MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has enrolled the first patient in its proprietary data collection App and machine learning algorithm, ZAM.
The company will log the data from the start of an observational study monitoring the effects of its epilepsy treatment, CannEpil™.
The European-based pharmaceutical company specialises in the production and development of plant-inspired medicines.
MXC will use data from the app to record daily metrics from patients, their symptoms and the impact of their treatment in order to establish a baseline.
The company, along with medical practitioners, will then be able to establish a detailed record of the study and an enhanced understanding of the effect of CannEpil™ on Refractory Epilepsy patients.
Better patient management
Ultimately, the data will lead to better patient management and care, giving patients reminders on how and when to take medication (per their medical practitioners’ advice). It will also help to measure treatment progress and have the ability for a qualified doctor to prescribe alternative medication following a consultation.
The trial is supported by the 'I am Billy' Foundation, a charity set up to aid parents and families in navigating the challenges of obtaining NHS-funded medical cannabis for children.
The NHS is the United Kingdom’s National Health Service.
“The enrolment of the first patient in the ZAM App in the UK enables us to fully record the impact and efficacy of our products undergoing trials,” co-founder and managing director of MGC Pharmaceuticals Roby Zomer said.
“Consolidation of data is of paramount importance in ensuring the safety and efficiency of MGC’s proprietary products, and we see the integration of both pharma and tech as a revolution in the clinical trial process.
“We are proud to be supporting the ‘I am Billy’ foundation in this endeavour, and are pleased to be recognised as a leading company in the sector.”